Novel lymphocyte-specific Rab GTPase in T cell differentiation
Novel lymphocyte-specific Rab GTPase in T cell differentiation
批准号:
9036856
负责人:
Yousang Gwack
金额:
$38.5万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2020-10-31
关键词:
AddressAmino AcidsAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAntibodiesAntigen-Presenting CellsAutoimmune DiseasesAutoimmunityBindingC-terminalCD4 Positive T LymphocytesCellsComplexDataDefectDiseaseEventExperimental Autoimmune EncephalomyelitisFamilyGTP BindingGene TargetingGenomicsGoalsGuanidinesGuanine NucleotidesGuanosine Triphosphate PhosphohydrolasesHelper-Inducer T-LymphocyteHumanImaging TechniquesImmuneImmune responseImmunologyInflammationInflammatoryInterferon Type IIKnockout MiceLeadLigationLymphocyteMAPK8 geneMediatingMembrane LipidsMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein KinasesMolecularMonomeric GTP-Binding ProteinsMusNucleotidesPathogenicityPathway interactionsPatientsPharmaceutical PreparationsPhysiologicalPlayProteinsReagentReceptor SignalingRecruitment ActivityRegulationResolutionRoleSignal TransductionSignaling MoleculeT Cell Receptor Signaling PathwayT cell differentiationT-Cell ActivationT-Cell ReceptorT-LymphocyteTestingTherapeuticTimeatorvastatinbasegenome-wideimmunological synapseinnovationisoprenoidmembernew therapeutic targetnovelnuclear factors of activated T-cellsprenylationprotein transportpublic health relevancerab GTP-Binding Proteinsrhorho GTP-Binding Proteinstherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): T cell receptor (TCR) ligation induces intracellular signaling cascades including the Ca2+-NFAT (nuclear factor of activated T cells) and MAPK (mitogen-activated protein kinase) pathways that play crucial roles in activation and differentiation of T cells. Defects in these pathways lead to immune deficiency or hypersensitive immune responses in humans and mice. The small GTPases, Ras, Rac and Rho are known to play a central role in activation of TCR signaling pathways and are therapeutic targets in autoimmune diseases. These small GTPases are recruited into the immunological synapse (IS), the interface between an antigen-presenting cell and a T cell via interactions with signaling adaptors and activate the downstream MAPK pathway. However, in contrast to Ras, Rac and Rho GTPases, little is known about the role of more than 60 members of the Rab GTPase family in T cell activation. Our long-term goal is to uncover the role of Rab GTPases in TCR signaling to identify novel therapeutic targets to alleviate autoimmunity. We have recently identified a novel Rab GTPase, "CRACR2A GTPase" that plays a key role in TCR signaling. Our preliminary data show that CRACR2A GTPase is a lymphocyte-specific large Rab GTPase with many functional domains in contrast to small GTPases. We found that CRACR2A GTPase translocates into the IS to activate the downstream JNK (c- Jun N-terminal kinase) MAPK pathway. Furthermore, it is highly expressed in TH1 cells and plays an important role in expression of IFN-γ and T-bet, and thus in autoimmunity. Our central hypothesis is that CRACR2A GTPase is recruited into the IS via protein interactions and regulates the JNK pathway to drive TH1 differentiation. The objective of this proposal is to identify 1) interacting partners, 2) GTP binding and prenylation-mediated regulation, and 3) the physiological role of CRACR2A GTPase in T cells using high resolution imaging techniques, genomics and conditionally targeted knockout mice. CRACR2A GTPase is the first example of a large molecule containing the small Rab GTPase domain. We expect to reveal a hitherto unknown mechanism of regulation of the JNK pathway in T cell differentiation. We are confident that we will also identify a unique signaling function of Rab GTPases, which are otherwise known to mediate only intracellular protein trafficking. These mechanistic studies will have significant impact on therapeutic exploitation of this novel GTPase to treat autoimmune diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Osteomucosal healing and immunity in medication-related osteonecrosis of the jaw
-
批准号:10870267
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2023
-
负责人:Yousang Gwack
-
依托单位:
Mechanism underlying regulation of Ca2+ signaling in local effector T cells
-
批准号:10350598
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Yousang Gwack
-
依托单位:
Distinctive role of ORAI3 channels in the effector T cell response
-
批准号:10054359
-
项目类别:
-
资助金额:$19.5万
-
财政年份:2020
-
负责人:Yousang Gwack
-
依托单位:
Mechanism underlying regulation of Ca2+ signaling in local effector T cells
-
批准号:10582524
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2020
-
负责人:Yousang Gwack
-
依托单位:
Development of an animal model of severe neutrophilic asthma
-
批准号:9814242
-
项目类别:
-
资助金额:$7.8万
-
财政年份:2019
-
负责人:Yousang Gwack
-
依托单位:
A new class of immunomodulator, CRAC channel blockers
-
批准号:8354166
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2012
-
负责人:Yousang Gwack
-
依托单位:
A new class of immunomodulator, CRAC channel blockers
-
批准号:8500190
-
项目类别:
-
资助金额:$21.71万
-
财政年份:2012
-
负责人:Yousang Gwack
-
依托单位:
Suppression of Immune Functions by a Peptide Blocking Function of CRAC Channels
-
批准号:8069982
-
项目类别:
-
资助金额:$19.06万
-
财政年份:2010
-
负责人:Yousang Gwack
-
依托单位:
Suppression of Immune Functions by a Peptide Blocking Function of CRAC Channels
-
批准号:7873630
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2010
-
负责人:Yousang Gwack
-
依托单位:
Novel regulators of store-operated Ca2+ entry in immune systems
-
批准号:8098129
-
项目类别:
-
资助金额:$37.73万
-
财政年份:2009
-
负责人:Yousang Gwack
-
依托单位:
Novel regulators of store-operated Ca2+ entry in immune systems
-
批准号:7697210
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2009
-
负责人:Yousang Gwack
-
依托单位:
Novel regulators of store-operated Ca2+ entry in immune systems
-
批准号:8489100
-
项目类别:
-
资助金额:$35.47万
-
财政年份:2009
-
负责人:Yousang Gwack
-
依托单位:
Novel regulators of store-operated Ca2+ entry in immune systems
-
批准号:7881747
-
项目类别:
-
资助金额:$38.12万
-
财政年份:2009
-
负责人:Yousang Gwack
-
依托单位:
Novel regulators of store-operated Ca2+ entry in immune systems
-
批准号:8282753
-
项目类别:
-
资助金额:$37.73万
-
财政年份:2009
-
负责人:Yousang Gwack
-
依托单位:
海外基金